Kruidvat Noodanticonceptie Ulipristal

Ulipristal acetate, the active ingredient in Kruidvat Noodanticonceptie Ulipristal, is a selective progesterone receptor modulator presented as an oral formulation for oral use. It is employed as emergency contraception to delay or inhibit ovulation and thereby prevent fertilisation in women of reproductive age.

GNH USA supplies Kruidvat Noodanticonceptie Ulipristal as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Ulipristal acetate is a selective progesterone receptor modulator used in emergency contraception to prevent pregnancy after unprotected intercourse.

- Unprotected intercourse: provides effective contraception when taken within 120 hours after exposure. - Contraceptive failure: offers an alternative to copper IUD when other emergency methods are unavailable. - Late‑cycle contraception: can be used in the luteal phase when regular hormonal methods are not feasible.

Ulipristal acetate may cause a range of adverse reactions. Most are mild and resolve without intervention.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headache. - Fatigue: feeling of tiredness or low energy. - Abdominal pain: cramp‑like discomfort in the lower abdomen. - Menstrual changes: spotting or delayed next period. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Liver injury: jaundice, dark urine, or elevated liver enzymes. - Persistent vomiting: may lead to dehydration. - Severe abdominal pain: could indicate ovarian torsion. - Anaphylaxis: rapid onset of systemic hypersensitivity. - Thromboembolic events: rare clot formation in veins or arteries.

Before using Kruidvat Noodanticonceptie Ulipristal, consider the following safety measures.

- Timing of administration: take as soon as possible after unprotected intercourse, ideally within 5 days. - Pregnancy status: confirm that the user is not already pregnant before taking the tablet. - Hormonal contraception: avoid initiating combined hormonal contraceptives on the same day, as efficacy may be reduced. - Known hypersensitivity: do not use if the individual has a documented allergy to ulipristal acetate or any excipients. - Drug interactions: be aware of concomitant use of strong CYP3A4 inducers which may lower effectiveness. - Store at ambient temperature: keep in the original pack, protect from moisture and excessive heat.

Ulipristal acetate can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness. - Simultaneous initiation of combined hormonal contraceptives: can diminish the emergency pill’s action.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., valproate): may modestly lower drug levels. - Antiretroviral agents (e.g., efavirenz): potential reduction in efficacy. - Herbal supplements such as St. John’s wort: may decrease plasma concentration. - Hormone‑based therapies (e.g., hormone replacement): monitor for reduced contraceptive effect.